Xenon Pharmaceuticals (XENE) Q1 2026 earnings summary

Executive summary

• Achieved significant progress in Q1 2026, highlighted by positive Phase 3 X-TOLE2 results for azetukalner in focal onset seizures, exceeding expectations and supporting NDA submission in Q3 2026.

• Expanded azetukalner's potential beyond epilepsy, with ongoing Phase 3 studies in major depressive disorder and bipolar depression, and advanced early-stage pain and epilepsy programs.

• No product sales to date; revenue is from collaboration milestones.

• Completed $747.5 million financing and raised $707.6 million net proceeds from a public offering, extending cash runway into 2029 and supporting transition to a commercial-stage company.

• Report covers the quarter ended March 31, 2026, with continued focus on neuroscience drug development.

Financial highlights

• Ended Q1 2026 with $1.34 billion in cash, cash equivalents, and marketable securities, up from $586 million at year-end 2025.

• Net loss widened to $102.3 million in Q1 2026 from $65.0 million in Q1 2025, driven by higher R&D and G&A expenses and lower collaboration revenue.

• R&D expenses rose to $88.5 million (from $61.2 million), G&A expenses increased to $23.8 million (from $19.0 million) year-over-year.

• No collaboration revenue recognized in Q1 2026, compared to $7.5 million in Q1 2025.

• Net cash provided by financing activities was $843.0 million, mainly from equity offerings.

Outlook and guidance

• NDA submission for azetukalner in focal onset seizures planned for Q3 2026, with anticipated FDA approval and DEA scheduling by late 2027 or early 2028.

• Topline data from X-NOVA2 (MDD) expected in H1 2027; first-in-human studies for XEN1701 (NaV1.7) and XEN1120 (Kv7) to complete in 2026.

• Continued focus on commercial readiness, payer engagement, and expanding field-based capabilities ahead of azetukalner launch.

• Cash runway projected to fund operations into 2029 based on current plans.

• Anticipate ongoing operating losses and need for additional capital in the future.